Initiating clozapine treatment service and characteristics of clozapine-treated patients in a general hospital in Addis Ababa, Ethiopia

被引:2
|
作者
Teferra, Solomon [1 ]
机构
[1] Addis Ababa Univ, Sch Med, Dept Psychiat, Addis Ababa, Ethiopia
关键词
clozapine; Ethiopia; mental health service; sub-Saharan Africa; treatment-resistant schizophrenia; TREATMENT-RESISTANT; TARDIVE-DYSKINESIA; CLINICAL-COURSE; ECONOMIC BURDEN; FOLLOW-UP; SCHIZOPHRENIA; MYOCARDITIS; MANAGEMENT;
D O I
10.4102/sajpsychiatry.v26i0.1418
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: At least one-third of patients with schizophrenia suffer from treatment-resistant schizophrenia needing treatment with clozapine. This is the first report on the experience of initiating clozapine service in Ethiopia. Aim: The aim of this study was to report the experience of setting up clozapine service and describe characteristics of patients treated with clozapine. Setting: This study was conducted in a general hospital in Addis Ababa, Ethiopia. Methods: Descriptive summary of the clozapine treatment service and review of characteristics of patients treated with clozapine were conducted. Clinical Global Impression (CGI) Scale and Abnormal Involuntary Movement Scale (AIMS) score were used to measure outcome. Quantitative data were analysed using Statistical Package for the Social Sciences (SPSS) Version 24. Results: It was possible to provide clozapine treatment in a general hospital using the national guideline. During the first year of initiation of the service, a total of 22 patients were treated. The majority were men (20/22, 90.9%) and in the age group of 30-44 years (11/22, 50%). Indications for clozapine were treatment-resistant schizophrenia (15/22, 68.2%) and tardive dyskinesia (7/22, 31.8%). The average dose of clozapine was 350 mg/day. Common side effects included sedation, constipation and excessive salivation. On CGI Scale, mean severity index score dropped from 5.18 at admission to 3.68 during discharge, and average AIMS score changed from 16.8 to 6.5. None of the patients developed agranulocytosis; however, three patients discontinued because of adverse effects. Conclusion: Establishing clozapine treatment service was possible in a general hospital in Ethiopia where psychiatric service run by psychiatrists was available. Mechanisms should be in place to ensure adherence to the national guideline.
引用
收藏
页码:1 / 6
页数:6
相关论文
共 50 条
  • [21] Unanticipated plasma concentrations in two clozapine-treated patients
    Alfaro, CL
    McClure, RK
    Vertrees, JE
    Benavides, R
    ANNALS OF PHARMACOTHERAPY, 2001, 35 (09) : 1028 - 1031
  • [22] Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels
    Heidi J . Wehring
    Teresa Elsobky
    Joseph P. McEvoy
    Gopal Vyas
    Charles M. Richardson
    Robert P. McMahon
    Bethany A. DiPaula
    Fang Liu
    Kelli Sullivan
    Robert W. Buchanan
    Stephanie Feldman
    Elizabeth M. McMahon
    Deanna L. Kelly
    Psychiatric Quarterly, 2018, 89 : 73 - 80
  • [23] Obsessive-compulsive symptoms in clozapine-treated schizophrenic patients
    Ertugrul, A
    Yagcioglu, AEA
    Eni, N
    Yazici, KM
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2005, 59 (02) : 219 - 222
  • [24] Cardiovascular Disease in Clozapine-Treated Patients: Evidence, Mechanisms and Management
    Ronaldson, Kathlyn J.
    CNS DRUGS, 2017, 31 (09) : 777 - 795
  • [25] Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels
    Wehring, Heidi J.
    Elsobky, Teresa
    McEvoy, Joseph P.
    Vyas, Gopal
    Richardson, Charles M.
    McMahon, Robert P.
    DiPaula, Bethany A.
    Liu, Fang
    Sullivan, Kelli
    Buchanan, Robert W.
    Feldman, Stephanie
    McMahon, Elizabeth M.
    Kelly, Deanna L.
    PSYCHIATRIC QUARTERLY, 2018, 89 (01) : 73 - 80
  • [26] Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia
    Fan, X.
    Borba, C. P. C.
    Copeland, P.
    Hayden, D.
    Freudenreich, O.
    Goff, D. C.
    Henderson, D. C.
    ACTA PSYCHIATRICA SCANDINAVICA, 2013, 127 (03) : 217 - 226
  • [27] Body weight gain in clozapine-treated patients: Is norclozapine the culprit?
    Jessurun, Naomi T.
    Derijks, Hieronymus J.
    van Marum, Rob J.
    Jongkind, Amy
    Giraud, Eline L.
    van Puijenbroek, Eugene P.
    Grootens, Koen P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (02) : 853 - 857
  • [28] Leukocytosis in Clozapine-treated Patients: a Sign of Loss of Response to the Antipsychotic
    Prisco, V.
    Iannaccone, T.
    Fabrazzo, M.
    EUROPEAN PSYCHIATRY, 2015, 30
  • [29] Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients
    Solismaa, Anssi
    Kampman, Olli
    Lyytikainen, Leo-Pekka
    Seppala, Niko
    Viikki, Merja
    Mononen, Nina
    Lehtimaki, Terho
    Leinonen, Esa
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 (05) : 442 - 449
  • [30] Leukocytosis in clozapine-treated patients: a sign of loss of response to the antipsychotic
    Prisco, V.
    Iannaccone, T.
    Volpe, U.
    Fabrazzo, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S484 - S484